BREAKING NEWS: FDA MEDICAL ADVISOR ACCUSES U.S. CONGRESS OF BEING OWNED BY PHARMA

After years of an increasingly close relationship between the FDA and the pharmaceutical industry, an insider is finally speaking out. Dr. Raeford Brown, a pediatric anesthesiologist at the University of Kentucky Children’s Hospital and chair of the Food and Drug Administration (FDA) Committee on Analgesics and Anesthetics, has been openly critical of big pharma and the lack of proper oversight from the FDA, according to a new article on Yahoo Finance.

Continue reading

Are Hospitals Working for Patients…or PROFITS?

On September 8th, 2018, the medical community was in severe shock. That was the day the New York Times broke the story that Dr. José Baselga, a world leading cancer specialist, was being paid millions by drug and medical device companies and not disclosing this information in hundreds of ‘independent’ medical articles he’s authored. Why is this one of the most important discoveries of the decade in the medical field?

Dr. Jose Baselga, who left MSK Hospital over reports he took millions in undisclosed money from the pharmaceutical industry.

Because as Chief Medical Officer of Memorial Sloane Kettering Hospital in New York City, one of the world’s leading cancer centers, Baselga had tremendous influence over the medical community. And the story shows how much influence the pharmaceutical industry has over world leading experts.

Although the New York Times focused on Memorial Sloane Kettering mostly, it’s clear in the series of articles that other hospitals have similar stories: a drive for profits that could put patients at risk.

From the New York Times article:

“The corporatization of this institution is clear to many of us who have been here a long time,” said Dr. Carol L. Brown, a gynecologic cancer surgeon, according to an audio recording of the meeting.

The meeting ended after several doctors advocated an immediate no-confidence vote in the hospital’s senior leadership. The turmoil followed reports by The New York Times and ProPublica that the hospital’s chief medical officer, Dr. José Baselga, had been paid millions by drug and health care companies and failed to disclose those ties more than 100 times in medical journals, and that hospital insiders had made lucrative side deals that stood to earn them handsome profits, sometimes for work they had done on the job.

When news of Dr. Baselga’s disclosure lapses broke in September, 12 doctors and researchers at the hospital served on the boards of publicly traded companies, more than at any other major cancer center, according to a review by The New York Times and ProPublica. Dr. Baselga has since resigned from the hospital and the two boards he served on. And a day after the physicians’ meeting on Oct. 1, Dr. Thompson resigned from the boards of the pharmaceutical giant Merck and Charles River Laboratories, a health care company, that together had paid him $585,050 in compensation in 2017.

For more facts on the long reach of the pharmaceutical industry, click here.

FDA Approves Gardasil For Adults, Even Though it’s Killing Teenagers

FDA approves use of HPV vaccine for adults 27 to 45

Initially, the FDA only approved the HPV vaccine for people aged 9 – 26. But on Friday, the use of the human papillomavirus vaccine called Gardasil 9 was approved for men and women between the ages of 27 and 45. (FOX59, See full article here)

The US Food and Drug Administration made the decision in an attempt to help prevent HPV-related diseases and cancers in a broader age range. However, there are 150 viruses that make up HPV and Gardasil 9 claims to protect against nine types of HPV. Yes – the nine types they claim to protect are responsible for the majority of the HPV related diseases, but most HPV infections actually go away on their own.

Continue reading

BREAKING NEWS: Big Pharma gives MILLIONS to patient associations and advocacy groups every year

Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year, reveals a new database Pre$cription for Power, which as logging 12,000 donations from large publicly traded drugmakers to such organizations.

The database shows that donations to patient advocacy groups tallied for 2015 (most recent available) dwarfed the total amount the companies spent on federal lobbying. The 14 companies that contributed $116 million to patient advocacy groups reported only about $63 million in lobbying activities that same year.

Continue reading

Ex-Pharma rep who refuses to vaccinate his newborn baby after working within the Pharma industry.

PLEASE WATCH!!

Ex-Pharma rep who refuses to vaccinate his newborn baby after working within the Pharma industry.
“In my experience, doctors don’t do outside research. They tell their patients whatever the Pharma rep tells them. And Pharma wants to keep you sick, that’s where the money is. Vaccines play into this and my son will never be vaccinated.”

EVERY PARENT NEEDS TO HEAR THIS. And every non-parent too because mandatory vaccines are coming for adults next. 271 vaccines in development — pharma’s next blockbuster product line.

Your doctor doesn’t have time to research — it’s up to you to show them the vaccine inserts. Pharma won’t. Because there are no gold-standard, placebo based safety studies in there, yet the toxic vaccine additives are there in black and white.

Read the ingredients and “safety” info so they can no longer ignore the TRUTH and they will begin to LISTEN TO PATIENTS more and Pharma less!

Be your own advocate!! Take back your HEALTH!!

Watch the video here: https://youtu.be/5ZY8Im_J3qU

 

 

NEW REPORT: PHARMA FUNDS 80% OF “PATIENT ADVOCACY” GROUPS

NEW REPORT: PHARMA FUNDS 80% OF “PATIENT ADVOCACY” GROUPS — How corrupt is the healthcare system so many people put blind faith into? Pharma money goes very far, including partly funding at least 80% of so-called patient advocacy groups.
Yes, you read that right. The “patient” groups that are so active in the media and with state and federal lawmakers. They are silently and subtly pushing an agenda and helping Pharma and NOT the patients.
Don’t trust what you hear, read and watch without really researching what you are putting into your body and weighing the risks. Most often, real health has nothing to do with the so-called “health”care system so many people rely on.
#LearnTheRisk #naturalHEALTH #realHEALTHnotpharmaWEALTH
Follow our Facebook PAGE for more insights into what’s really going on with our health: Learn The Risk
Join our GROUP for support & resources: www.facebook.com/Groups/learntherisk
www.LearnTheRisk.org

More Than 80 Percent of Patient Groups Accept Drug Industry Funds, Study Shows

The nation’s largest patient advocacy groups are on the front lines of some of the biggest health care debates, from the soaring costs of prescription drugs to whether new medicines are being approved quickly enough.

But while their voices carry weight because they represent the interests of sick patients, a new study has found that more than 80 percent of them accept funding from drug and medical-device companies. For some groups, the donations from industry accounted for more than half of their annual income, and in nearly 40 percent of cases, industry executives sit on governing boards, according to the study, which is published in The New England Journal of Medicine.

Nearly “nine out of every 10 are taking money,” said Dr. Ezekiel J. Emanuel, an oncologist and vice provost at the University of Pennsylvania. He is one of the authors of the study, which looked at the top 104 nonprofit patient advocacy groups that reported more than $7.5 million in annual revenues for 2014. “I think that is not well known — I think that is a shock.”

Dr. Emanuel, who previously advised President Obama on health care, said patient groups were far less transparent about conflicts of interest than medical researchers, who are now pushed to disclose ties to the drug and device industries when they write articles and make public appearances.

“Compared to what researchers are doing, this is pathetic,” he said. And yet “they wrap themselves in white as if they’re pure.”

Patient groups said they have taken steps in recent years to improve their financial disclosures and conflict-of-interest policies, and rejected the suggestion that they were influenced by their corporate donors.

“Patient advocacy organizations are driven by their missions — putting patients first,” said Marc M. Boutin, the chief executive of the National Health Council, an umbrella group for patient-advocacy groups. “To say otherwise negates the extraordinary work achieved by these organizations on behalf of their patients.” The health council had previously said that pharmaceutical companies accounted for 62 percent of the council’s $3.5 million budget in 2015.

The study also found a wide disparity in how the groups disclose the donations, making it difficult for members of the public to know how significant the industry funding is. The study authors gathered their data by examining the websites of the nonprofit groups, as well as their tax filings and annual reports from 2014.

The researchers pointed to the National Hemophilia Foundation as one group that is vague about its funding because, although it lists corporate donors, it only discloses donation ranges. Drug makers contributed a range from $8.5 million to $14 million of the group’s $16.8 million annual budget in 2014, the year researchers studied. Its top donors, Baxter, Biogen and Novo Nordisk, make products used by people with hemophilia; each donated between $2 million and $3 million, the researchers said.

The American Diabetes Association, by contrast, reported receiving more than $28 million in industry funding in 2014, or about 15 percent of its budget, but provided detailed disclosures of which companies donated, and how much, the study authors said.

In a statement, the hemophilia foundation said it never allows its corporate sponsors to influence its decision-making, and that it also does not endorse specific products or favor certain companies. It declined to provide precise dollar amounts of contributions from companies, saying that the foundation complied with “accepted financial reporting standards.”